Beilu Pharmaceutical Obtains GMP Certification from ANVISA

2024/11/01

Recently, Beijing Beilu Pharmaceutical Co., Ltd.'s contrast agent production linepassed the GMP (Good Manufacturing Practice) certification by Brazil's National Health Surveillance Agency (ANVISA).

Brazil is the largest country in South America. Beilu Pharmaceutical's successful passing of the Brazil's ANVISA GMP certification this time has created conditions for the company's contrast agent products to successfully enter the Brazilian market and has a very positive effect on the company further expanding the Brazilian market and other international markets.

In the first three quarters of 2024, Beilu Pharmaceutical's overseas market business progressed smoothly, with continuous growth in overseas revenue. While the pace of overseas registration for contrast agent products is accelerating, Hichi Pharmaceuticals' iodine APIs continue to expand in the overseas market, and gadolinium APIs produced by the Cangzhou subsidiary are also gradually achieving internationalization. At present, the company's products have been sold to 26 countries, with additional registrations ongoing in 30 other countries or regions. As the company successfully passes the ANVISA GMP certification, the competitiveness of its products in international markets will be further enhanced, and the pace of internationalization is expected to accelerate.

PREV : Beilu Pharma's Contrast Media Production Line Passed EU GMP Certification.

NEXT : Hichi Pharmaceutical's Iodixanol API Approved for Market

References

Related Products

Ioversol

Iopamidol Intermediate (order based) 5-Amino-2,4,6- triiodisophthaloyl acid dichloride

Traditional Chinese Medicine-Jiuweizhenxin Granules

Related Beilu News

Beijing Beilu Pharmaceutical's subsidiary, Hichi Pharmaceutical, has obtained GMP certification from the Brazilian National Health Surveillance Agency (ANVISA)
September 2, 2025Recently, the company's holding subsidiary, Hichi Pharmaceutical, passed the official on-site GMP (Good Manufacturing Practice) certification of the Brazilian National Health Surveillance Agency (...view
[New Product] Beilu Pharma's Ioversol Injection Receives Approval
May 14, 2026Recently, Beilupharma received the Drug Registration Certificate for its Ioversol Injection, approved and issued by the National Medical Products Administration (NMPA).The original innovat...view
New Specifications of Repaglinide Tablets from Beilu Pharma Were Deemed to Have Passed the Generic Drugs Quality and Efficacy Consistency Evaluation
December 20, 2021Now, our company received the Notification of Approval of Supplementary Application for Repaglinide Tablets issued by the State Medical Products Administration (Notification No. : 2021 B04618). After ...view
【New Product】Beilu Pharmaceutical's Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets Approved
May 10, 2024Recently, Beilu Pharmaceutical received a Drug Registration Certificate from the National Medical Products Administration for Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets with a s...view
Beilu Pharmaceutical Jiuwei Zhenxin granule was selected into the Quotscience and Technology Innovation Chinaquot New Drug Achievement
November 30, 2021Recently, Beilu Pharmaceutical Jiuwei Zhenxin Granules were successfully selected into the "Science and Innovation China" New Drug Achievement Case Library of the China Association for Scien...view
Beilu Pharmaceutical's Sees Strong Start to 2025 with Q1 Revenue and Profit Growth
April 25, 2025Recently, Beilu Pharmaceutical (300016) released the "2025 First Quarter Report". Building on the stable growth in annual performance in 2024, Beilu Pharmaceutical has had a great start in 2...view

Beilu Pharmaceutical Obtains GMP Certification from ANVISA

Beijing Beilu Pharmaceutical's subsidiary, Hichi Pharmaceutical, has obtained GMP certification from the Brazilian National Health Surveillance Agency (ANVISA)

[New Product] Beilu Pharma's Ioversol Injection Receives Approval

New Specifications of Repaglinide Tablets from Beilu Pharma Were Deemed to Have Passed the Generic Drugs Quality and Efficacy Consistency Evaluation

【New Product】Beilu Pharmaceutical's Paroxetine Hydrochloride Enteric-Coated Sustained-Release Tablets Approved

Beilu Pharmaceutical Jiuwei Zhenxin granule was selected into the Quotscience and Technology Innovation Chinaquot New Drug Achievement

Beilu Pharmaceutical's Sees Strong Start to 2025 with Q1 Revenue and Profit Growth